NCT07364019 The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia
| NCT ID | NCT07364019 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Dementia Prevention |
| Study Type | INTERVENTIONAL |
| Enrollment | 700 participants |
| Start Date | 2026-05-07 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 700 participants in total. It began in 2026-05-07 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will recruit participants at risk for dementia to participate in an online educational program called Brain Health PRO (BHPro). The BHPro intervention is designed to address modifiable risk factors for dementia through a 6-month, fully online, educational program conveying the best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health. Achieving lifestyle changes in a diverse Canadian population through online education would be a major achievement in dementia prevention in Canada, with widespread personal and socioeconomic benefits. Eligible participants will be randomly assigned to either start Brain Health PRO immediately or in 6 months (delayed-start control group). All participants will have the opportunity to have access to BHPro for 6 months during the course of the study and will have open access to all content for 12 months following the initial 6-month intervention. Participation will last from 18-24 months depending on group assignment.
Eligibility Criteria
Inclusion Criteria: * Completion and documentation of the electronic Informed Consent Process (from the participant) * Sufficient proficiency in English or French to undergo online assessments and participate in an online educational program. * Technical ability to participate in an online educational program and remote assessments (i.e., regularly have access to a computer or tablet with an internet connection; have access to a desktop or laptop computer with an internet connection at least once every 6 months; ability to send and receive emails; ability to complete online assessments) * Sufficient vision to participate in an online educational program and complete online cognitive testing * Ages 50-80 * Classified as being at increased risk of dementia based on at least one of the following: * First-degree family history of dementia * Education level at or below high school (grade 12 or less) * Self-Reported: Hypertension, Hypercholesterolemia, Body Mass Index \> 30 kg/m2 (derived from NIH Metric BMI Calculator), or Physical Inactivity (active is defined as engaging in a minimum of 20- 30 min of physical activity causing sweating and breathlessness, at least 2 times a week) Exclusion Criteria: * Individuals who have a clinical diagnosis of Dementia (based on self-report) * Individuals who are currently participating in or have participated in a past study involving BHPro
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07364019 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Dementia Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07364019 currently recruiting?
Yes, NCT07364019 is actively recruiting participants. Contact the research team at penny.slack@ubc.ca for enrollment information.
Where is the NCT07364019 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT07364019 clinical trial?
NCT07364019 is sponsored by University of British Columbia. The trial plans to enroll 700 participants.